IBL HEALTHCARE LIMITED

CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE HALF YEAR ENDED DECEMBER 31, 2022 - UNAUDITED

		Quarter ended		Half year ended	
		December 31, 2022	December 31, 2021	December 31, 2022	December 31
	Note	+	The state of the s	es '000 ———	
Revenue from contracts with customers	18	1,026,329	960,786	2,025,816	1,773,365
Cost of sales	19	(662,851)	(625,128)	(1,356,279)	(1,162,672)
Gross profit		363,478	335,658	669,537	610,693
Other loss	20	(42,790)	(6,267)	(47,864)	(9,707)
Marketing and distribution expenses		(136,238)	(152,059)	(295,562)	(283,830)
Administrative and general expenses		(25,194)	(22,979)	(49,060)	(46,355)
Finance cost	21	(17,814)	(5,492)	(31,014)	(11,678)
Profit before taxation		141,442	148,861	246,037	259,123
Income tax expense	22	(45,201)	(57,360)	(74,781)	(84,827)
Profit after taxation		96,240	91,501	171,256	174,296
Other comprehensive income					-
Total comprehensive income		96,240	91,501	171,256	174,296
			(Restated)		(Restated)
Earnings per share - Basic	23	1.35	1.28	2.40	2.44
					Alex

The annexed notes 1 to 28 form an integral part of these condensed interim financial statements.

Chief Executive

Director

Chief Financial Officer

